Matrix GRIN

9 Key Findings from Your GRIN Surveys (and why you need to come back and complete more)

by | Jul 13, 2023 | 0 comments

In June, CMT researchers, clinicians, industry leaders and patient advocacy group leaders met in Copenhagen, Denmark for the annual Peripheral Nerve Society meeting. The Hereditary Neuropathy Foundation’s Global Registry for Inherited Neuropathies (GRIN) was the center of attention during the poster presentation by the team at Hackensack Meridian Health.

Their study aimed to evaluate the impact of neuropathic pain on the psychosocial well-being of individuals with Charcot-Marie-Tooth (CMT) disease, a hereditary neuropathy. In summary, this study highlights the significant impact of neuropathic pain on the quality of life and psychosocial well-being of individuals with CMT. It also emphasizes the importance of addressing pain management strategies and promoting interprofessional care to improve patient outcomes.

Here are the key findings and conclusions:

  1. Neuropathic Pain in CMT: The majority of patients with CMT experience mild to moderate neuropathic pain at least once per week. Neuropathic pain was found to be a significant contributor to the disease burden reported by patients.
  2. Pain Severity and Quality of Life: Pain severity was associated with diminished life satisfaction and increased social isolation. Participants with more severe, neuropathic-type pain reported lower life satisfaction and higher levels of social isolation. Life satisfaction scores decreased with increasing pain severity.
  3. Exercise Engagement: Participants with pain reported lower engagement in daily exercise compared to those without pain. Respondents with pain reported 10% lower engagement in more than 30 minutes of daily exercise.
  4. Opioid Use: High rates of opioid use for neuropathic pain were observed among the survey population, with 27.2% of patients reporting the use of opioids. This highlights the need for education and awareness regarding evidence-based pain treatment options.
  5. Interprofessional Treatment: The study suggests that interprofessional treatment of neuropathic pain may improve both psychosocial and physical outcomes in individuals with CMT.
  6. Gender and Pain: Females younger than 65 years old reported more severe pain compared to females older than 65 and males in both age groups.
  7. Prevalence of Neuropathic Pain: The majority of respondents (63.95%) experienced neuropathic-type pain based on the generated T-scores.
  8. Study Limitations: The self-reported diagnoses of CMT were not confirmed with genetic reports, potentially including individuals with misdiagnosed CMT in the study population.
  9. Future Directions: A second generation of the Global Registry for Inherited Neuropathies (GRIN) was commissioned to acquire more genetic reports, allowing for diagnostic confirmation and stratification by CMT subtype.
  10. The time is NOW to participate in CMT Research by completing the three *NEW* GRIN Surveys: Natural History Survey v2 + Lifestyle Survey + Medication Survey

View Poster 

HNF is happy to announce that the Global Registry for Inherited Neuropathies Natural History Study for Charcot-Marie-Tooth is now listed at Identifier: NCT05902351


Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news